A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.

@article{Yang2014AND,
  title={A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.},
  author={Chi-Chen Yang and Han-Shu Hu and R Wu and Szu-Huei Wu and Shiow-Ju Lee and W T Jiaang and Jyh-Haur Chern and Z S Huang and H. C. Wu and Chung-Ming Chang and Andrew Yueh},
  journal={Antimicrobial agents and chemotherapy},
  year={2014},
  volume={58 1},
  pages={110-9}
}
Dengue virus (DENV) causes disease globally, resulting in an estimated 25 to 100 million new infections per year. No effective DENV vaccine is available, and the current treatment is only supportive. Thus, there is an urgent need to develop therapeutic agents to cure this epidemic disease. In the present study, we identified a potential small-molecule inhibitor, BP13944, via high-throughput screening (HTS) of 60,000 compounds using a stable cell line harboring an efficient luciferase replicon… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…